Ovid Therapeutics (OVID)

Executive Summary

Ovid Therapeutics is a biopharmaceutical company focused on developing novel therapies for rare neurological diseases, including epilepsies and neurodevelopmental disorders. The company's pipeline features three lead candidates: OV329, a GABA-aminotransferase inhibitor for treatment-resistant seizures; OV350, a direct activator of the KCC2 transporter; and OV882, a gene therapy for SYNGAP1-related intellectual disability. Ovid's strategy is to advance these programs through clinical development, potentially with strategic partners. As a publicly traded entity (NASDAQ: OVID), the company is positioned to address significant unmet medical needs in neurology. Ovid's recent progress includes continued enrollment in early-stage trials for OV329 and preclinical advancements for OV350 and OV882. The company is nearing key milestones, including initial efficacy data from its seizure program and regulatory filings for its gene therapy candidate. While still early in development, Ovid's focused pipeline and orphan drug designations provide a clear regulatory pathway. The next 6–12 months will be pivotal as the company reports data from its lead programs, which could de-risk the pipeline and drive shareholder value.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 interim data for OV329 in treatment-resistant seizures40% success
• Q1 2027IND filing or Phase 1 initiation for OV350 (KCC2 activator)60% success
• Q4 2026Preclinical proof-of-concept data for OV882 gene therapy in SYNGAP135% success